☆ 4.8 Article

Periprocedural Bridging Management of Anticoagulation

CIRCULATION (2012)

Journal

CIRCULATION

Volume 126, Issue 4, Pages 486-490

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1161/CIRCULATIONAHA.112.092833

Keywords

atrial fibrillation; deep vein thrombosis; heparin; mechanical heart valve; rivaroxaban; warfarin; dabigatran

Categories

Cardiac & Cardiovascular Systems Peripheral Vascular Disease

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Multidisciplinary Sciences

Effectiveness and safety of non-vitamin K direct oral anticoagulants in atrial fibrillation patients with bioprosthetic valve

Inki Moon, Tae-Hwa Go, Jang Young Kim, Dae Ryong Kang, Suk Ho Sohn, Hyun-Jung Lee, Jae-Woong Choi, Jun-Bean Park, Ho-Young Hwang, Hyung-Kwan Kim, Yong-Jin Kim, Kyung-Hwan Kim, Seung-Pyo Lee

Summary: This study suggests that non-vitamin K direct oral anticoagulant (DOAC) may be an excellent alternative to warfarin for the prevention of systemic embolic events in patients with nonvalvular atrial fibrillation (AF) and bioprosthetic heart valve (BPHV).

PLOS ONE (2022)

Add to Collection

Article Medicine, General & Internal

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding

Gregory Y. H. Lip, Allison Keshishian, Yan Zhang, Amiee Kang, Amol D. Dhamane, Xuemei Luo, Christian Klem, Mauricio Ferri, Jenny Jiang, Huseyin Yuce, Steven Deitelzweig

Summary: In this study of patients with NVAF and high risk of GI bleed, NOACs were associated with lower rates of stroke and/or SE, but NOACs had varying risks of MB compared with warfarin. These results may help inform treatment options in this patient population.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair

Amgad Mentias, Marwan Saad, Madonna Michael, Shady Nakhla, Venu Menon, Serge Harb, Pulkit Chaudhury, Douglas Johnston, Walid Saliba, Oussama Wazni, Lars Svensson, Milind Y. Desai, Samir Kapadia

Summary: Direct oral anticoagulants (DOACs) are associated with higher risk of ischemic stroke but lower risk of bleeding in patients with bioprosthetic valve replacement compared with warfarin, while DOACs are associated with lower risk of all three outcomes in patients with mitral valve repair in atrial fibrillation compared with warfarin.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

Add to Collection

Article Pharmacology & Pharmacy

Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients with Atrial Fibrillation

Shin-Yi Lin, Sung-Chun Tang, Ching-Hua Kuo, Li-Ting Ho, Yen-Bin Liu, Yu-Fong Peng, Li-Kai Tsai, Chih-Fen Huang, Jiann-Shing Jeng

Summary: This study reports on the association between direct oral anticoagulant (DOAC) concentration and clinical outcomes in Asian patients with atrial fibrillation (AF). The proportion of DOAC concentrations falling outside the expected range was higher than reported in clinical trials. Low trough concentration was associated with increased risk of systemic thromboembolism (SSE), while high trough concentration was associated with major bleeding. Measurement of trough DOAC concentration should be considered for patients at risk of concentration deviations.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Multidisciplinary Sciences

Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population

Giorgio Ciminata, Claudia Geue, Olivia Wu, Manuela Deidda, Noemi Kreif, Peter Langhorne

Summary: This study aimed to explore the methodological challenges of using real-world evidence (RWE) to estimate comparative effectiveness of anticoagulants in Scotland. The results showed that different methods, such as propensity score (PS) matching, inverse probability weighting (IPW), and covariate adjustment with PS, performed well in different subgroups of the study population.

PLOS ONE (2022)

Add to Collection

Article Medicine, General & Internal

Atrial Fibrillation

Gregory F. Michaud, William G. Stevenson

Summary: A 63-year-old healthy male with atrial fibrillation presents with symptoms of dyspnea and irregular heartbeat. Physical examination reveals high blood pressure, irregular pulse, and ECG confirms atrial fibrillation. Further evaluation and treatment plan are needed.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study

Anneka Mitchell, Julia Snowball, Tomas J. Welsh, Margaret C. Watson, Anita McGrogan

Summary: The study found a significant increase in the prescribing of oral anticoagulants for atrial fibrillation patients aged 75 years and older, but disparities still exist based on age and comorbidities. Elderly patients and those with comorbidities such as dementia, history of falls, major bleeds, and fractures were less likely to be prescribed oral anticoagulants.

BMC MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Incidence of Osteoporosis in Primary Care Patients with Atrial Fibrillation Receiving Different Oral Anticoagulants

Woldesellassie M. Bezabhe, Jan Radford, Barbara C. Wimmer, Mohammed S. Salahudeen, Ivan Bindoff, Gregory M. Peterson

Summary: The use of DOACs is associated with a lower risk of osteoporosis compared to warfarin, with each individual DOAC having a significantly lower risk as well.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry

Paul L. Hess, Kensey L. Gosch, Sandeep M. Jani, Paul D. Varosy, Steven M. Bradley, Thomas M. Maddox, P. Michael Ho, Salim S. Virani

Summary: This study analyzed the use of oral anticoagulants among patients with valvular atrial fibrillation from 2013 to 2019 using the PINNACLE Registry. The results showed variations in the use of direct oral anticoagulants and warfarin, but consistent trends in their usage over time.

AMERICAN HEART JOURNAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants

Ji Yun Lee, Il-Young Oh, Ju-Hyeon Lee, Seok Kim, Jihoon Cho, Charg Hyun Park, Sooyoung Yoo, Soo-Mee Bang

Summary: This study examined the impact of potential drug-drug interactions on the risk of ischemic stroke and major bleeding in atrial fibrillation patients treated with DOACs. It was found that an increased number of DDIs significantly raised the risk of both ischemic stroke and hospitalization for major bleeding in these patients.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Clinical Neurology

Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants A Nationwide Cohort Study

Yi-Hsin Chan, Tze-Fan Chao, Hsin-Fu Lee, Shao-Wei Chen, Pei-Ru Li, Jia-Rou Liu, Lung-Sheng Wu, Shang-Hung Chang, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip

Summary: This study found that in patients with atrial fibrillation and cancer, NOACs have a lower risk of major adverse cardiovascular events, major adverse limb events, venous thrombosis, and major bleeding compared to warfarin. The results support the consideration of thromboprophylaxis with NOACs instead of warfarin for this patient population.

STROKE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy

Nijole Bernaitis, Tony Badrick, Shailendra Anoopkumar-Dukie

Summary: This study found that when patients with atrial fibrillation were switched from warfarin to a non-vitamin K oral anticoagulant (NOAC), the potential for pharmacokinetic (PK) drug interactions significantly reduced but remained around 40%. Identifying and managing potential PK drug interactions with NOACs remains a priority to optimize the clinical benefit of these anticoagulants.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)

Add to Collection

Article Clinical Neurology

Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation

Alexandros A. Polymeris, Kosmas Macha, Maurizio Paciaroni, Duncan Wilson, Masatoshi Koga, Manuel Cappellari, Sabine Schaedelin, Annaelle Zietz, Nils Peters, David J. Seiffge, David Haupenthal, Luise Gassmann, Gian Marco De Marchis, Ruihao Wang, Henrik Gensicke, Svenja Stoll, Sebastian Thilemann, Nikolaos S. Avramiotis, Bruno Bonetti, Georgios Tsivgoulis, Gareth Ambler, Andrea Alberti, Sohei Yoshimura, Martin M. Brown, Masayuki Shiozawa, Gregory Y. H. Lip, Michele Venti, Monica Acciarresi, Kanta Tanaka, Maria Giulia Mosconi, Masahito Takagi, Rolf H. Jager, Keith Muir, Manabu Inoue, Stefan Schwab, Leo H. Bonati, Philippe A. Lyrer, Kazunori Toyoda, Valeria Caso, David J. Werring, Bernd Kallmuenzer, Stefan T. Engelter

Summary: This study investigated the safety and effectiveness of DOAC versus VKA in patients aged >= 85 years with atrial fibrillation after recent stroke. The results showed that there was no significant difference in the composite outcome risk between DOAC and VKA in the oldest old patients.

ANNALS OF NEUROLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation

Catherine G. Derington, Glenn K. Goodrich, Stanley Xu, Nathan P. Clark, Kristi Reynolds, Jaejin An, Daniel M. Witt, David H. Smith, Maureen O'Keeffe-Rosetti, Daniel T. Lang, P. Michael Ho, T. Craig Cheetham, Angela C. Comer, Jordan B. King

Summary: This cohort study compared three direct oral anticoagulant (DOAC) care models for patients with atrial fibrillation (AF) and found that neither the usual care plus a population management tool (PMT) nor pharmacist-managed care model showed appreciably better outcomes for patients receiving DOAC compared with usual care.

JAMA NETWORK OPEN (2023)

Add to Collection

Article Medicine, General & Internal

Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry

Agnieszka Kaplon-Cieslicka, Monika Gawalko, Monika Budnik, Beata Uzieblo-Zyczkowska, Pawel Krzesinski, Katarzyna Starzyk, Iwona Gorczyca-Glowacka, Ludmila Danilowicz-Szymanowicz, Damian Kaufmann, Maciej Wojcik, Robert Blaszczyk, Jaroslaw Hiczkiewicz, Katarzyna Lojewska, Katarzyna Mizia-Stec, Maciej T. Wybraniec, Katarzyna Kosmalska, Marcin Fijalkowski, Anna Szymanska, Miroslaw Dluzniewski, Maciej Haberka, Michal Kucio, Blazej Michalski, Karolina Kupczynska, Anna Tomaszuk-Kazberuk, Katarzyna Wilk-Sledziewska, Renata Wachnicka-Truty, Marek Kozinski, Pawel Burchardt, Piotr Scislo, Radoslaw Piatkowski, Janusz Kochanowski, Grzegorz Opolski, Marcin Grabowski

Summary: Atrial fibrillation and flutter increase the risk of left atrial thrombus. Chronic oral anticoagulation can reduce the prevalence of left atrial thrombus. The risk of left atrial thrombus appears to be higher with vitamin K antagonists compared to non-vitamin K antagonist oral anticoagulants, and similar among different non-vitamin K antagonist oral anticoagulants.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Hematology

Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism

Waldemar E. Wysokinski, Damon E. Houghton, Ana I. Casanegra, Danielle T. Vlazny, Dalene M. Bott-Kitslaar, David A. Froehling, David O. Hodge, Lisa G. Peterson, Robert D. Mcbane

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection

Article Hematology

Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial

Robert D. McBane, Charles L. Loprinzi, Aneel Ashrani, Charles J. Lenz, Damon Houghton, Tyler Zemla, Jennifer G. Le-Rademacher, Waldemar E. Wysokinski

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis

Harry E. Fuentes, Robert D. McBane, Waldemar E. Wysokinski, Alfonso J. Tafur, Charles L. Loprinzi, Mohammad H. Murad, Irbaz Bin Riaz

MAYO CLINIC PROCEEDINGS (2019)

Add to Collection

Article Hematology

Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban

Damon E. Houghton, Ana I. Casanegra, Lisa G. Peterson, Jordan Cochuyt, David O. Hodge, Danielle Vlazny, Robert D. McBane, David Froehling, Waldemar E. Wysokinski

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Hematology

Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight

Waldemar E. Wysokinski, David A. Froehling, Damon E. Houghton, Robert D. McBane, Danielle T. Vlazny, Dalene M. Bott-Kitslaar, Wiktoria Kuczmik, Karolina Sutkowska, Kaja Bator, David O. Hodge, Lisa G. Peterson, Ana Casanegra

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Calf Vein Thrombosis Outcomes Comparing Anticoagulation and Serial Ultrasound Imaging Management Strategies

Wiktoria Kuczmik, Waldemar E. Wysokinski, Thanila Macedo, David Froehling, Paul Daniels, Ana Casanegra, Damon Houghton, Danielle Vlazny, Ryan Meverden, Teresa Lang, Launia White, David Hodge, Robert D. McBane

Summary: A comparison of management strategies for patients with calf deep vein thrombosis (DVT) found that patients treated with anticoagulants had better outcomes, with lower rates of venous thromboembolism (VTE) recurrence and DVT propagation compared to those managed with serial ultrasound surveillance only. Additionally, the net clinical benefit favored anticoagulant therapy over surveillance alone, without increasing bleeding outcomes.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Medicine, General & Internal

Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19-Positive Compared With COVID-19-Negative Patients

Rahul Chaudhary, Leslie Padrnos, Ewa Wysokinska, Rajiv Pruthi, Sanjay Misra, Meera Sridharan, Waldemar Wysokinski, Robert D. I. I. I. I. McBane, Damon E. Houghton

Summary: The study found that COVID-19-positive patients had longer hospital stays and a higher requirement for intensive care unit care, but observed fewer comorbidities. There was no significant difference in the incidence of venous thromboembolic events between COVID-19-positive and COVID-19-negative patients.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Medicine, General & Internal

Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism

Damon E. Houghton, Danielle T. Vlazny, Ana Casanegra, Nichole Brunton, David A. Froehling, Ryan A. Meverden, David O. Hodge, Lisa G. Peterson, Robert D. McBane, Waldemar E. Wysokinski

Summary: The study compared bleeding risk in patients with GI cancer and non-GI cancer receiving anticoagulation for acute Ca-VTE, finding that there was no significant difference in major bleeding or CRNMB between the two groups. Apixaban had a higher rate of major bleeding in patients with luminal GI cancer compared to non-GI cancer and to enoxaparin in luminal GI cancer patients, while rivaroxaban showed no increased risk of major bleeding in GI cancer patients.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Review Medicine, General & Internal

Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis

Irbaz Bin Riaz, Harry E. Fuentes, Syed Arsalan Ahmed Naqvi, Huan He, Qurat-Ul-Ain Riaz Sipra, Alfonso J. Tafur, Leslie Padranos, Waldemar E. Wysokinski, Ariela L. Marshall, Per Olav Vandvik, Victor Montori, Alan H. Bryce, Hongfang Liu, Robert G. Badgett, Mohammad Hassan Murad, Robert D. McBane

Summary: Direct oral anticoagulants (DOACs) are more effective and safe than low-molecular-weight heparin in the treatment of cancer-associated thrombosis (CAT) in adults. Apixaban and rivaroxaban are more effective than dalteparin in reducing recurrent venous thromboembolism (VTE) events. Edoxaban has a higher risk of major bleeding compared to dalteparin, while rivaroxaban has a higher risk of clinically relevant nonmajor bleeding compared to dalteparin and other DOACs. There are no significant differences between DOACs in terms of VTE recurrences and major bleeding.

MAYO CLINIC PROCEEDINGS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Single versus multiple and incidental versus symptomatic subsegmental pulmonary embolism: clinical characteristics and outcome

Yumiko Hirao-Try, Danielle T. Vlazny, Ryan Meverden, Damon E. Houghton, Ana Casanegra, David A. Froehling, David O. Hodge, Lisa G. Peterson, Robert D. McBane, Waldemar E. Wysokinski

Summary: The study found differences in the clinical profile of patients with single versus multiple subsegmental pulmonary embolism (SSPE) in terms of symptomatic presentation and coexisting DVT, but similar clinical outcomes. Patients with single SSPE experienced more episodes of major bleeding compared to the multiple SSPE group, while the death rate was higher for single SSPE patients, but this difference disappeared after adjusting for cancer. Additionally, patients with incidental SSPE had similar clinical outcomes to those with symptomatic SSPE.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2022)

Add to Collection

Article Hematology

Risk of venous thromboembolism after COVID-19 vaccination

Damon E. Houghton, Waldemar Wysokinski, Ana Casanegra, Leslie J. Padrnos, Surbhi Shah, Ewa Wysokinska, Rajiv Pruthi, Aneel Ashrani, Meera Sridharan, Lisa Baumann-Kreuziger, Robert McBane, Anand Padmanabhan

Summary: This study analyzed the incidence of VTE before and after COVID-19 vaccination. The results showed that there was no increased risk of acute VTE post-vaccination for the authorized vaccines in the United States.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

Incidental pulmonary embolism in cancer and noncancer patients: Prospective cohort study

Ewa M. Wysokinska, Damon E. Houghton, Danielle T. Vlazny, Aneel A. Ashrani, David A. Froehling, Ryan Meverden, David O. Hodge, Lisa G. Peterson, Robert D. McBane, Waldemar E. Wysokinski, Ana Casanegra

Summary: The clinical condition of incidental pulmonary embolism (iPE) is more serious compared to symptomatic pulmonary embolism (sPE), as indicated by higher mortality and major bleeding rates. However, these differences are primarily driven by underlying comorbidities rather than the severity of the embolic event.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Hematology

Venous thromboembolism after COVID-19 vaccination in patients with thrombophilia

Damon E. Houghton, Waldemar E. Wysokinski, Leslie J. Padrnos, Surbhi Shah, Ewa Wysokinska, Rajiv Pruthi, Atefeh Ghorbanzadeh, Aneel Ashrani, Meera Sridharan, Robert D. McBane, Anand Padmanabhan, Ana I. Casanegra

Summary: This study aimed to investigate the risk of venous thromboembolism (VTE) in patients with thrombophilia who received COVID-19 vaccinations. The analysis of electronic medical records from November 1, 2020, to November 1, 2021, showed no increased risk of acute VTE after vaccination compared to the pre-vaccination period in this subgroup of patients.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes

Nichole E. Brunton, Waldemar E. Wysokinski, David O. Hodge, Danielle T. Vlazny, Damon E. Houghton, Ana I. Casanegra

Summary: In patients with acute VTE, a small percentage experienced anticoagulation delay, often due to modifiable reasons. While VTE recurrence and CRNMB were not significantly different, there was a higher rate of mortality and major bleeding in patients with delayed anticoagulation initiation, indicating a need for further investigation.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Von Willebrand Factor and ADAMTS13 as Predictors of Adverse Outcomes in Patients With Nonvalvular Atrial Fibrillation

Waldemar E. Wysokinski, Rowlens M. Melduni, Naser M. Ammash, Danielle T. Vlazny, Ewa Konik, Rayya A. Saadiq, Izabela Gosk-Bierska, Joshua Slusser, Diane Grill, Robert D. Mcbane

Summary: The study showed that von Willebrand factor (VWF) is an independent predictor of poor outcomes including death and a composite of death and thromboembolism in patients with nonvalvular atrial fibrillation.

CJC OPEN (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.